Posted by Michael Wonder on 31 Aug 2021
Schedule of Pharmaceutical Benefits - 1 September 2021 update
1 September 2021 - The September 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The September issue of the Schedule includes a few new/revised listings:
- Abiraterone acetate (Zytiga) - restriction change
- Adrenaline (Anapen) - new formulation
- Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides (Essential Care Jr) - new formulation
- Brentuximab vedotin (Adcetris) - new indication
- Cariprazine hydrochloride (Reagila) - new medicine
- Deferasirox (Deferasirox Juno) - new formulation
- Enzalutamide (Xtandi) - restriction change
- High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (K. Yo) - new formulation
- Lacosamide (Vimpat) - new indication
- Obeticholic acid (Ocaliva) - new medicine
- Semaglutide (Ozempic) - new indication
- Teduglutide (Revestive) - restriction change
- Vedolizumab (Entyvio) - new formulation
Read Summary of PBS changes
Posted by:
Michael Wonder